{"id":14951,"date":"2025-09-14T13:12:51","date_gmt":"2025-09-14T12:12:51","guid":{"rendered":"https:\/\/resemedicin.se\/reseradet\/?p=14951"},"modified":"2025-09-15T13:26:39","modified_gmt":"2025-09-15T12:26:39","slug":"2025-09-14-rsv-vaccination-58-83-skydd-mot-sjukhusvard-hos-aldre","status":"publish","type":"post","link":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-09-14-rsv-vaccination-58-83-skydd-mot-sjukhusvard-hos-aldre\/","title":{"rendered":"2025-09-14 RSV-vaccination: 58\u201383 % skydd mot sjukhusv\u00e5rd hos \u00e4ldre"},"content":{"rendered":"\n<p>Tv\u00e5 nya real-world-studier visar att en dos RSV-vaccin ger betydande skydd mot sjukhusv\u00e5rd bland \u00e4ldre. I <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2509810\" target=\"_blank\" rel=\"noreferrer noopener\">en dansk fas-4-studie<\/a> (randomiserad \u00f6ppen pr\u00f6vning) under s\u00e4songen 2024\/25 uppskattades skyddseffekten f\u00f6r Abrysvo\u00ae hos personer &gt;60 \u00e5r till&nbsp;83%&nbsp;mot sjukhusinl\u00e4ggning f\u00f6r RSV-orsakad luftv\u00e4gssjukdom; \u00e4ven f\u00e4rre sjukhusinl\u00e4ggningar s\u00e5gs f\u00f6r RSV-nedre luftv\u00e4gsinfektion (VE 92 %) och f\u00f6r all respiratorisk sjukhusv\u00e5rd (VE 15 %). <\/p>\n\n\n\n<p>En <a href=\"https:\/\/jamanetwork.com\/journals\/jama\/article-abstract\/2838490\" target=\"_blank\" rel=\"noreferrer noopener\">amerikansk multicenterstudie<\/a> (test-negativ fall-kontrollstudie) ber\u00e4knade total&nbsp;vaccineffekt (VE) till 58%&nbsp;mot RSV-relaterad sjukhusv\u00e5rd \u00f6ver tv\u00e5 s\u00e4songer efter 1 dos RSV-vaccin; med 69% skydd om vaccinationen skett samma s\u00e4song och&nbsp;48 %&nbsp;om den skett f\u00f6reg\u00e5ende s\u00e4song. \u00c5lders- och riskgruppsanalyser visade&nbsp;46%&nbsp;VE hos 60\u201374 \u00e5ringar respektive&nbsp;68%&nbsp;hos \u00e4ldre \u226575 \u00e5r,&nbsp;72%&nbsp;VE mot respiratorv\u00e5rd eller d\u00f6d, och l\u00e4gre VE hos immunsupprimerade (30%) \u00e4n hos immunkompetenta (67%). F\u00f6rfattarna betonar behovet av fortsatt uppf\u00f6ljning f\u00f6r att klarl\u00e4gga skyddets varaktighet och optimala revaccinationsintervall.<\/p>\n\n\n\n<p><strong>Reser\u00e5dets kommentar (Sverige):<\/strong><br>Resultaten st\u00f6djer g\u00e4llande svenska rekommendationer att erbjuda RSV-vaccination till&nbsp;alla som fyller 75 \u00e5r&nbsp;samt till&nbsp;60\u201374-\u00e5ringar i medicinska riskgrupper. St\u00f6rst nytta v\u00e4ntas n\u00e4r vaccinationen ges&nbsp;inf\u00f6r aktuell s\u00e4song&nbsp;och kan planeras tillsammans med \u00f6vriga h\u00f6stvaccinationer enligt regionala rutiner.<\/p>\n\n\n\n<p style=\"font-size:12px\"><em><strong>EpiNytt\u00a0<\/strong><\/em>\u00e4r Reser\u00e5dets kostnadsfria omv\u00e4rldsbevakning med aktuell information om\u00a0utbrott och nyheter p\u00e5 vaccin- och resefronten. Se\u00a0<a href=\"https:\/\/resemedicin.se\/reseradet\/epinytt\/\">hela listan med nyheter i fulltext<\/a>. Dela g\u00e4rna l\u00e4nken med intresserade kolleger, vilka ocks\u00e5 sj\u00e4lva kan\u00a0<a href=\"https:\/\/resemedicin.se\/reseradet\/prenumerera-kostnadsfritt-pa-epinytt\/\">prenumerera p\u00e5 nyhetsbrevet<\/a>\u00a0utan kostnad.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tv\u00e5 nya real-world-studier visar att en dos RSV-vaccin ger betydande skydd mot sjukhusv\u00e5rd bland \u00e4ldre. I en dansk fas-4-studie (randomiserad \u00f6ppen pr\u00f6vning) under s\u00e4songen 2024\/25 uppskattades skyddseffekten f\u00f6r Abrysvo\u00ae hos personer &gt;60 \u00e5r till&nbsp;83%&nbsp;mot sjukhusinl\u00e4ggning f\u00f6r RSV-orsakad luftv\u00e4gssjukdom; \u00e4ven f\u00e4rre sjukhusinl\u00e4ggningar s\u00e5gs f\u00f6r RSV-nedre luftv\u00e4gsinfektion (VE 92 %) och f\u00f6r all respiratorisk sjukhusv\u00e5rd (VE 15 &hellip; <a href=\"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-09-14-rsv-vaccination-58-83-skydd-mot-sjukhusvard-hos-aldre\/\" class=\"more-link\">Forts\u00e4tt l\u00e4sa<span class=\"screen-reader-text\"> \u201d2025-09-14 RSV-vaccination: 58\u201383 % skydd mot sjukhusv\u00e5rd hos \u00e4ldre\u201d<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"aside","meta":{"_lmt_disableupdate":"no","_lmt_disable":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-14951","post","type-post","status-publish","format-aside","hentry","category-epinytt","post_format-post-format-aside"],"modified_by":"Reser\u00e5det","jetpack_featured_media_url":"","jetpack-related-posts":[{"id":14984,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-09-26-nirsevimab-77-skyddande-mot-rsv-sjukhusinlaggning-hos-spadbarn\/","url_meta":{"origin":14951,"position":0},"title":"2025-09-26 Nirsevimab 77 % skyddande mot RSV-sjukhusinl\u00e4ggning hos sp\u00e4dbarn","author":"Reser\u00e5det","date":"2025-09-26","format":"aside","excerpt":"En ny\u00a0multinationell kohortstudie\u00a0fr\u00e5n RSV-s\u00e4songen\u00a02024\u201325\u00a0visar att\u00a0nirsevimab (Beyfortus)\u00a0var\u00a077 % effektivtmot\u00a0RSV-relaterad sjukhusinl\u00e4ggning\u00a0hos sp\u00e4dbarn. Studien omfattade\u00a0409 723 sp\u00e4dbarn\u00a0i\u00a0USA, Kanada, Libanon och Saudiarabien, med data ur\u00a0Epic Cosmos\u00a0(\u22481 700 sjukhus, 40 000 mottagningar). Totalt registrerades\u00a03 385 RSV-inl\u00e4ggningar, varav\u00a0850\u00a0bland nirsevimab-exponerade och\u00a02 535\u00a0bland icke-exponerade. \u00c4ven\u00a0IVA-inl\u00e4ggningar\u00a0(324\u00a0vs\u00a0765) och\u00a0intubationer\u00a0(49\u00a0vs\u00a090) var f\u00e4rre i den behandlade gruppen. F\u00f6rfattarna konkluderar att nirsevimab fortsatt minskar\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":15807,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2026-01-11-vinterns-luftvagsvirus-ah3n2-i-ny-tappning-och-rsv-pa-uppgang\/","url_meta":{"origin":14951,"position":1},"title":"2026-01-11 Vinterns luftv\u00e4gsvirus: A(H3N2) i ny tappning och RSV p\u00e5 uppg\u00e5ng","author":"Reser\u00e5det","date":"2026-01-12","format":"aside","excerpt":"Luftv\u00e4gsvirusaktiviteten har \u00f6kat tydligt i Europa under inledningen av 2026, med Iinfluensa\u00a0 som det dominerande viruset och med tecken till \u00f6kande RSV-cirkulation i flera l\u00e4nder. S\u00e4songen har startat tidigare \u00e4n normalt i stora delar av Europa och pr\u00e4glas av en omfattande spridning av influensa A, framf\u00f6r allt subtypen A(H3N2). Influensa\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2026\/01\/image-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2026\/01\/image-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2026\/01\/image-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2026\/01\/image-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2026\/01\/image-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2026\/01\/image-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":15027,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-01-05-rsv-vaccin-bekraftat-sakert-och-effektivt-enligt-ny-cochrane-oversikt\/","url_meta":{"origin":14951,"position":2},"title":"2025-10-05 RSV-vaccin \u2013 bekr\u00e4ftat s\u00e4kert och effektivt enligt ny Cochrane-\u00f6versikt","author":"Reser\u00e5det","date":"2025-10-05","format":"aside","excerpt":"En ny systematisk \u00f6versikt fr\u00e5n\u00a0Cochrane Collaboration, publicerad i september 2025, bekr\u00e4ftar att\u00a0RSV-vacciner \u00e4r b\u00e5de effektiva och s\u00e4kra\u00a0f\u00f6r vuxna och \u00e4ldre personer. Analysen omfattade\u00a0\u00f6ver 100 000 studiedeltagare\u00a0i flera randomiserade fas 3-studier. Resultaten visar att vaccination\u00a0minskar risken f\u00f6r RSV-orsakad luftv\u00e4gsinfektion med cirka 80 %\u00a0och\u00a0sv\u00e5r sjukdom med upp till 90 %\u00a0under den f\u00f6rsta\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":15925,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2026-02-02-rsv-profylax-nt-radets-rekommendation-om-beyfortus-kvarstar-aven-sasongen-2026-2027\/","url_meta":{"origin":14951,"position":3},"title":"2026-02-02 RSV-profylax: NT-r\u00e5dets rekommendation om Beyfortus\u00ae kvarst\u00e5r \u00e4ven s\u00e4songen 2026\/2027","author":"Reser\u00e5det","date":"2026-02-02","format":"aside","excerpt":"NT-r\u00e5dets nationella rekommendation f\u00f6r profylax mot RSV med den monoklonala antikroppen nirsevimab (Beyfortus\u00ae) f\u00f6r s\u00e4songen 2025\/2026 kommer att forts\u00e4tta g\u00e4lla \u00e4ven under RSV-s\u00e4songen 2026\/2027. Avtalet med l\u00e4kemedelsf\u00f6retaget har f\u00f6rl\u00e4ngts i syfte att s\u00e4kerst\u00e4lla fortsatt tillg\u00e5ng till l\u00e4kemedlet. Rekommendationen inneb\u00e4r att Beyfortus\u00ae \u00e4ven forts\u00e4ttningsvis ska anv\u00e4ndas f\u00f6r prevention av RSV-infektion hos\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":13570,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-05-25-arets-influensa-rsv-sasong-ar-over-i-europa-men-covid-19-mojligen-pa-vag-upp\/","url_meta":{"origin":14951,"position":4},"title":"2025-05-25 \u00c5rets influensa\/RSV-s\u00e4song \u00e4r \u00f6ver i Europa, men covid-19 m\u00f6jligen p\u00e5 v\u00e4g upp","author":"Reser\u00e5det","date":"2025-05-25","format":"aside","excerpt":"Data som rapporterades till ECDC vecka 20, 2025, tyder p\u00e5 att andelen patienter i EU\/EES-l\u00e4nderna som s\u00f6ker v\u00e5rd f\u00f6r luftv\u00e4gsinfektioner i prim\u00e4rv\u00e5rden eller v\u00e5rdas f\u00f6r sv\u00e5r luftv\u00e4gsinfektion (SARI) p\u00e5 sjukhus nu \u00e5terg\u00e5tt till en baslinjeniv\u00e5. Det uppt\u00e4cks ocks\u00e5 f\u00e5 fall av influensa i diagnostiska prover (<10% i samtliga l\u00e4nder). \u00c4ven\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/05\/image-12.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/05\/image-12.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/05\/image-12.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/05\/image-12.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/05\/image-12.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/05\/image-12.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":13818,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-06-05-nt-radet-beyfortus-till-riskbarn-infor-rsv-sasongen-2025-26\/","url_meta":{"origin":14951,"position":5},"title":"2025-06-05 NT-r\u00e5det: Beyfortus\u00ae till riskbarn inf\u00f6r RSV-s\u00e4songen 2025\/26","author":"Reser\u00e5det","date":"2025-06-05","format":"aside","excerpt":"Regionernas samverkansmodell f\u00f6r l\u00e4kemedel, NT-r\u00e5det, har i ett yttrande till regionerna rekommendera att Beyfortus (nirsevimab) ges som profylax mot RSV-infektion till barn f\u00f6dda fr\u00e5n och med 10 september 2025. Beyfortus ges vid f\u00f6rlossning\/BB-verksamhet antingen direkt efter f\u00f6dseln innan hemg\u00e5ng, eller vid ett ordinarie \u00e5terbes\u00f6k. NT-r\u00e5dets rekommendation till regionerna inf\u00f6r s\u00e4songen\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts\/14951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/comments?post=14951"}],"version-history":[{"count":2,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts\/14951\/revisions"}],"predecessor-version":[{"id":14955,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts\/14951\/revisions\/14955"}],"wp:attachment":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/media?parent=14951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/categories?post=14951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/tags?post=14951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}